Patagonia is developing a robust pipeline of products focused on rare skin conditions.  We have recently completed a Phase IIa study for PAT-001 for congenital ichthyosis.  If you are interested in participating in a future study, please visit

IPEG   Technology

Patagonia’s technologies are based on its proprietary IPEG™ delivery system.  Our IPEG system enables us to optimize API delivery to pathologic skin layers while minimizing systemic absorption and removing irritating excipients.


Expanded Access Statement

At this time, Patagonia does not have an Expanded Access policy.  As the development of our programs evolve, we will periodically reassess our policy and post any updates to our website.  For more questions, please contact  

 Developing Treatments for Rare Dermatological Diseases

Patagonia Pharmaceuticals, LLC

50 Tice Blvd, Suite A26

Woodcliff Lake, NJ 07677

For more info:

© 2019 by Patagonia Pharmaceuticals, LLC